US Stock MarketDetailed Quotes
STAB Statera Biopharma
- 0.000600
- 0.0000000.00%
15min DelayClose Aug 23 16:00 ET
42.85KMarket Cap0.00P/E (TTM)
0.000600High0.000600Low638Volume0.000600Open0.000600Pre Close0.38Turnover0.00%Turnover Ratio0.00P/E (Static)71.42MShares0.03760052wk High0.00P/B38.30KFloat Cap0.00000152wk Low--Dividend TTM63.84MShs Float279.800000Historical High--Div YieldTTM0.00%Amplitude0.000001Historical Low0.000000Avg Price1Lot Size
Statera Biopharma Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | (Q3)Sep 30, 2021 | (Q2)Jun 30, 2021 | (Q1)Mar 31, 2021 | (FY)Dec 31, 2020 | (Q4)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 94.73%-801.52K | 94.42%-168.51K | -45.11%-3.76M | -454.75%-28.19M | -324.31%-7.36M | -15.22M | -3.02M | -166,927.77%-2.59M | -2,014.30%-5.08M | 3.28M |
| Net income from continuing operations | 73.64%-3.36M | 47.15%-3.49M | -46.78%-7.76M | -742.37%-101.88M | -1,726.25%-77.25M | ---12.73M | ---6.61M | -715.70%-5.29M | -275.12%-12.09M | ---4.23M |
| Depreciation and amortization | 37.42%191.75K | 6,457.58%131.09K | 15,080.68%120.23K | 26,887.75%255.57K | 11,858.08%113.24K | --139.54K | --2K | --792 | --947 | --947 |
| Other non cash items | -168.48%-357.2K | 49.70%354.83K | -99.63%1.1K | -129.82%-1.3M | ---2.36M | --521.62K | --237.04K | -40.36%298.21K | 132.67%4.36M | ---- |
| Change In working capital | 169.54%3.01M | 182.44%3.9M | 491.16%3.42M | 2,189.33%1.07M | 965.99%3.43M | ---4.33M | --1.38M | 295.26%579.28K | -104.60%-51.04K | --321.96K |
| -Change in receivables | -87.82%53.33K | ---131.14K | --65.13K | ---94.52K | ---532.42K | --437.91K | --0 | --0 | --0 | --0 |
| -Change in prepaid assets | 105.56%149.49K | --252.79K | --482.1K | ---981.9K | --1.71M | ---2.69M | --0 | --0 | --0 | --0 |
| -Change in payables and accrued expense | 280.99%2.76M | 138.99%3.39M | 247.99%2.57M | 256.66%1M | 18.21%371.63K | ---1.53M | --1.42M | 411.85%739.51K | -59.52%280.84K | --314.4K |
| -Change in other current assets | 148.99%204.64K | 230.37%47.35K | 394.29%471.52K | 398.69%991.29K | 21,126.11%1.61M | ---417.72K | ---36.32K | -7,799.38%-160.22K | -179.97%-331.88K | --7.56K |
| -Change in other current liabilities | ---- | ---- | ---- | ---92.72K | ---- | ---- | ---- | ---- | --0 | --0 |
| -Change in other working capital | ---163.29K | --344.39K | ---167.64K | --242.64K | --373.47K | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 94.73%-801.52K | 94.42%-168.51K | -45.11%-3.76M | -454.75%-28.19M | -324.31%-7.36M | ---15.22M | ---3.02M | -166,927.77%-2.59M | -2,014.30%-5.08M | --3.28M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | -37.76%-6.45K | 139,801.04%13.46M | -3,104.76%-96.91K | 13.04M | 519.65K | -4.69K | -9.64K | -3.02K |
| Net PPE purchase and sale | --0 | --0 | -37.76%-6.45K | -1,798.62%-182.97K | -3,104.79%-96.91K | ---63.27K | ---18.11K | ---4.69K | ---9.64K | ---3.02K |
| Net business purchase and sale | ---- | ---- | ---- | --13.65M | --1 | ---- | ---- | ---- | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | -37.76%-6.45K | 139,801.04%13.46M | -3,104.76%-96.91K | --13.04M | --519.65K | ---4.69K | ---9.64K | ---3.02K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 5.93%711.65K | -97.23%500K | -234.49%-2.9M | 269.24%20.99M | 102.98%89.42K | 671.79K | 18.07M | 2.16M | 2,360.61%5.68M | -3M |
| Net issuance payments of debt | --0 | -96.64%500K | ---9.3M | --13.77M | -923.15%-1M | ---97.74K | --14.87M | --0 | --0 | ---97.74K |
| Net common stock issuance | --0 | ---2 | --6.41M | 445.78%7.34M | 136.87%1.66M | --5.69M | --0 | --0 | --1.35M | ---4.5M |
| Net preferred stock issuance | ---- | --0 | --0 | --0 | ---- | ---- | --3.53M | --2.16M | --4.4M | --1.66M |
| Net other financing activities | ---- | ---- | ---135 | -109.84%-129.26K | ---569.53K | --769.53K | ---- | ---- | ---61.6K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 5.93%711.65K | -97.23%500.13K | -234.50%-2.9M | 269.24%20.99M | 102.98%89.42K | --671.79K | --18.07M | --2.16M | 2,360.61%5.68M | ---3M |
| Net cash flow | ||||||||||
| Beginning cash position | -96.48%553.75K | 0.18%152.18K | 1,052.57%6.84M | 35,892.06%593.87K | 4,341.11%14.22M | --15.72M | --151.91K | 35,892.06%593.87K | -85.03%1.65K | --320.11K |
| Current changes in cash | 94.02%-89.87K | -97.87%331.62K | -1,408.40%-6.67M | 956.62%6.26M | -2,791.03%-7.37M | ---1.5M | --15.57M | -28,376.55%-441.96K | 6,420.37%592.22K | --273.76K |
| Effect of exchange rate changes | 2,196.18%42.22K | --69.95K | ---26.09K | ---6.65K | ---4.64K | ---2.01K | --0 | --0 | --0 | --0 |
| End cash Position | -96.44%506.1K | -96.48%553.75K | 0.18%152.18K | 1,052.57%6.84M | 1,052.57%6.84M | --14.22M | --15.72M | 154,913.27%151.91K | 35,892.06%593.87K | --593.87K |
| Free cash flow | 94.76%-801.52K | 94.46%-168.51K | -45.09%-3.77M | -457.30%-28.38M | -327.48%-7.46M | ---15.28M | ---3.04M | -167,229.64%-2.6M | -2,018.31%-5.09M | --3.28M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg